Research ArticleCancer
Silencing HoxA1 by Intraductal Injection of siRNA Lipidoid Nanoparticles Prevents Mammary Tumor Progression in Mice
- Amy Brock1,*,†,
- Silva Krause2,*,
- Hu Li1,*,‡,
- Marek Kowalski1,
- Michael S. Goldberg3,
- James J. Collins1,4 and
- Donald E. Ingber1,2,§
- 1Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA.
- 2Vascular Biology Program, Boston Children’s Hospital and Department of Pathology, Harvard Medical School, Boston, MA 02115, USA.
- 3Dana-Farber Cancer Research Institute, Harvard Medical School, Boston, MA 02115, USA.
- 4Howard Hughes Medical Institute, Boston University, Boston, MA 02115, USA.
- ↵§Corresponding author. E-mail: don.ingber{at}wyss.harvard.edu
-
↵* These authors contributed equally to this work.
-
↵† Present address: Department of Biomedical Engineering and Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712, USA.
-
↵‡ Present address: Center for Individualized Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
See allHide authors and affiliations
Science Translational Medicine 01 Jan 2014:
Vol. 6, Issue 217, pp. 217ra2
DOI: 10.1126/scitranslmed.3007048
